Latest price and market analysis of Upadacitinib in 2025

Upadacitinib is a selective JAK1 inhibitor developed by AbbVie. It is mainly used to treat chronic inflammatory diseases such as moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. In 2023, upadatinib was officially launched in China and included in the national medical insurance directory, greatly improving its treatment accessibility. Patients can purchase medicines at regular domestic medical institutions with prescriptions and enjoy partial reimbursement according to local medical insurance policies.

Although Upatinib has been included in medical insurance, its original drug price is still relatively expensive. Common specifications are 15mg 30 tablets or 30mg 30 tablets. The price of each box may be as high as several thousand yuan before medical insurance. The actual out-of-pocket amount after reimbursement is greatly affected by the medical insurance policy of the patient's location, and usually fluctuates around a thousand yuan. Therefore, patients can consult the hospital pharmacy or medical insurance center before purchasing drugs to understand the local reimbursement ratio and final drug purchase expenditure.

In addition to original drugs, many countries have also launched generic versions on the market, among which the version produced by Lucius Pharmaceutical Company of Laos is the most famous. The dosage form of this generic drug is similar to that of the original drug, and it is sold through formal channels in many places overseas. According to the current market conditions, a box of Lucius version of Upatinib is priced at about 500 to 600 yuan, which is more affordable than the domestic original drug and is suitable for patients who take medicine for a long time and are under great financial pressure.

Patients should be extremely cautious when choosing purchase channels. Whether they are original drugs or generic drugs, they should obtain them through regular hospitals, cross-border medical platforms or legal overseas pharmacies to avoid purchasing counterfeit drugs that may affect the treatment effect. During the medication process, you should strictly follow the doctor's instructions and regularly review blood routine, liver and kidney function and other indicators to prevent adverse reactions. Overall, with the expansion of medical insurance coverage and overseas channels, upadatinib's market accessibility and economic burden will improve in 2025, and patients will have more diversified treatment options.

Reference materials:https://www.drugs.com/